ArticleScience advances2026
Contrast-sparing CT using renal-clearable gold nanoclusters for early spatial mapping of renal dysfunction.
Article in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Early, noninvasive, and spatially resolved assessment of renal dysfunction is essential for theranostics of kidney diseases, yet clinical biomarkers are criticized for averaging whole-kidney function and missing focal or unilateral injury. Here, we present a contrast-sparing computed tomography (CT) approach that maps renal dysfunction at the compartment level using renal-clearable glutathione-gold nanoclusters (GSH-Au NCs). The merits of ultrasmall hydrodynamic size (2.8 nanometers) and high x-ray attenuation ability enable GSH-Au NCs with fast renal clearance and robust intrarenal CT contrast. In three mechanistically distinct mouse models of acute kidney injury, low-dose GSH-Au NCs produced mechanism-specific imaging signatures and distinct time-attenuation behaviors, even before biomarkers changed. Notably, at an ultralow dose (32.5 milligrams of Au per kilogram), early bilateral cisplatin injury can be easily detected with an obvious bright band at the outer medulla area on CT, consistent with tubular injury and a cast/debris-mediated mechanism. This work establishes a dose-efficient CT workflow for early, noninvasive, spatial mapping of renal dysfunction, supporting diagnosis, classification, and monitoring of kidney disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.